- Joined
- Oct 11, 2003
- Messages
- 1,253
- Reaction score
- 44
Nature 435, 1108-1112 (23 June 2005) | doi: 10.1038/nature03658
An endocannabinoid mechanism for stress-induced analgesia
Andrea G. Hohmann1, Richard L. Suplita1, Nathan M. Bolton1, Mark H. Neely1, Darren Fegley2, Regina Mangieri2, Jocelyn F. Krey3, J. Michael Walker3, Philip V. Holmes1, Jonathon D. Crystal1, Andrea Duranti4, Andrea Tontini4, Marco Mor5, Giorgio Tarzia4 and Daniele Piomelli2
Top of page
Abstract
Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stress-induced analgesia1, is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB1 receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol2 (2-AG) and anandamide3. A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase4, 5, selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB1-dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase6, which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target.
An endocannabinoid mechanism for stress-induced analgesia
Andrea G. Hohmann1, Richard L. Suplita1, Nathan M. Bolton1, Mark H. Neely1, Darren Fegley2, Regina Mangieri2, Jocelyn F. Krey3, J. Michael Walker3, Philip V. Holmes1, Jonathon D. Crystal1, Andrea Duranti4, Andrea Tontini4, Marco Mor5, Giorgio Tarzia4 and Daniele Piomelli2
Top of page
Abstract
Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stress-induced analgesia1, is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB1 receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol2 (2-AG) and anandamide3. A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase4, 5, selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB1-dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase6, which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target.